This Wednesday, the US pharmaceutical Pfizer has presented new data from its own study that suggests that a third dose of the vaccine against Covid-19 can «strongly» boost protection against the delta variant, compared to the two-dose scheme.
The preliminary study, and which has not been subjected to peer review, shows that with a third dose of the serum the levels of antibodies against the delta variant are five times higher in people between 18 and 55 years , and in people 65 At age 85, the number of antibodies grows 11 times more than the second dose.
With this data, Pfizer calculates that a booster dose could multiply the neutralization of the delta variant by 100 . «We continue to believe that a third booster dose is likely to be needed within six to 12 months of full vaccination to maintain the highest level of protection, and studies are underway to evaluate the safety and immunogenicity of a third dose. «, they have indicated after the communiqué.
According to new safety and efficacy data published by Pfizer and its partner BioNtech , the overall efficacy of the vaccine remains at 91% during the first six months, reaching its highest point, 96.2%, between one week and two months after administering the second dose.
However, from the fourth and sixth months after receiving the full regimen, the effectiveness drops to 83.7%, with an average decrease of approximately 6% in the last two months. This research, in which 44,000 people from the United States and other countries participated, has also not been peer-reviewed
«The companies hope to publish more definitive data on the analysis and all accumulated data will be shared as part of current discussions with the FDA, the EMA (European Medicines Agency) and other regulators in the coming weeks,» they have indicated.
The drugmaker announced earlier this month that they intended to request authorization from the US Food and Drug Administration (FDA) to supply a third dose of the anticovid vaccine. With this study they hope that the FDA will modify the authorization of emergency use of the drug to give a booster injection starting in August in the United States.